Photophobia News and Research

RSS

A promising cellular target for migraine attacks

A recent study published in the journal Cephalalgia, the official journal of the International Headache Society, reported an intriguing discovery.

17 Dec 2019

New drug 'ubrogepant' may work for migraine

A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.

19 Nov 2019

New migraine-associated mechanism discovered

A mutation in the gen that codes the ionic channel TRESK -involved in the control of neuron irritability- causes the dysfunction of some neurons that increase neuronal activity and induce migraine pain.

29 Mar 2019

Study findings may provide insight into excessive light sensitivity experienced by some people

The eyes are for seeing, but they have other important biological functions, including automatic visual reflexes that go on without awareness. The reflexive system of the human eye also produces a conscious, visual experience, according to a new study from researchers in the Perelman School of Medicine and School of Arts and Sciences at the University of Pennsylvania.

31 Oct 2017

Viral RNAs make use of cell's transportation system, study finds

Flaviviruses are a significant threat to public health worldwide, and some infected patients develop severe -- potentially fatal -- neurological diseases.

1 Sep 2017

Color-tinted sunglasses may provide relief from photophobia in post-concussion patients

Following a concussion or mild traumatic brain injury (TBI), patients may suffer from light sensitivity or photophobia, making it challenging to return to normal activities.

5 Jul 2017

Exposing headache sufferers to pure-wavelength green light can lessen severity of migraines

Most migraine and post-traumatic headache sufferers find their headaches get worse in light, leading them to quit their most fundamental daily tasks and seek the comfort of darkness.

17 May 2016

New technologies go far beyond traditional use of contact lenses for vision correction

Imagine contact lenses that can deliver medicines directly to the eye, slow progression of nearsightedness in children, or monitor glucose levels in patients with diabetes.

1 Apr 2016

Vienna researchers investigate new light therapy treatment for people with migraines

Migraines often involve heightened sensitivity to light. In a project funded by the Austrian Science Fund FWF, a team of researchers from the Medical University of Vienna is investigating new therapies to treat light sensitivity, which greatly disturbs those affected.

9 Feb 2016

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed.

25 Mar 2015

Bright daylight could trigger panic attack

Fear of bright daylight is associated with panic disorder, according to new presented at the ECNP congress in Berlin.

21 Oct 2014

Early intervention hope for childhood achromatopsia

Researchers have found that children with achromatopsia have milder foveal pathology than their older counterparts, highlighting a potential opportunity for early intervention with gene therapy.

20 Aug 2014

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Pharmaceutical scientists at the University of Sunderland have been awarded £125,000 by the Cystinosis Foundation (CF) UK to fund the next stage of their research into a rare genetic disease.

7 Mar 2013

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.

7 Feb 2013

Selective laser trabeculoplasty promising for glaucoma

Selective laser trabeculoplasty leads to significant reductions in intraocular pressure in people with primary open-angle glaucoma, a study has found.

6 Feb 2013

Rigid gas-permeable lenses correct vision after ocular trauma

Fitting a rigid gas-permeable contact lens into the eyes of patients treated surgically for ocular trauma can improve their visual acuity and are well tolerated, report researchers from China.

7 Sep 2012

Corticosteroids needed after DALK to avert stromal rejection

Like those undergoing penetrating keratoplasty, patients treated with deep anterior lamellar keratoplasty may benefit from taking postoperative corticosteroids to prevent stromal rejection, report US researchers.

5 Sep 2012

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Acucela Inc., a clinical stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 3 clinical trial to evaluate rebamipide ophthalmic suspension in patients with dry eye syndrome.

19 Jul 2012